Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5873MR)

This product GTTS-WQ5873MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5873MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4559MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ12492MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ8407MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ1594MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ12043MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ12526MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ11696MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ13024MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW